How to Source Tranexamic Acid for Cosmetics: Pharma Grade vs Cosmetic Grade | Onerchem
How to Source Tranexamic Acid for Cosmetics: Pharma Grade vs Cosmetic Grade & What to Verify
Tranexamic Acid occupies an unusual position in the cosmetic ingredient market — it has decades of pharmaceutical history as a systemic antifibrinolytic drug, and a more recent but well-documented role as a topical brightening active. This dual-market background creates specific sourcing considerations that buyers need to understand before placing an order.
Pharmaceutical grade vs cosmetic grade — what actually differs
Tranexamic Acid (CAS 1197-18-8, trans-4-(aminomethyl)cyclohexane-1-carboxylic acid) is manufactured by a well-established chemical synthesis route and is commercially available in both pharmaceutical and cosmetic grades. Understanding the difference prevents two common mistakes: overpaying for pharmaceutical specifications that add no cosmetic value, and underpaying for inadequate documentation that creates regulatory exposure.
Why TXA works — the mechanism every buyer should understand
Understanding Tranexamic Acid's mechanism matters for sourcing because it determines what quality attributes are efficacy-critical versus what is supplier marketing language.
Tranexamic Acid is a synthetic lysine analogue. Its primary cosmetic mechanism is plasmin inhibition — it competitively blocks the lysine-binding sites on plasminogen, preventing its conversion to active plasmin. In the context of post-inflammatory hyperpigmentation (PIH):
- ✓Plasmin inhibition — TXA blocks plasmin, which would otherwise stimulate arachidonic acid release from keratinocyte membranes. Less arachidonic acid means less prostaglandin E2 production.
- ✓Prostaglandin cascade interruption — Reduced prostaglandin E2 means reduced activation of melanocyte-stimulating hormone (MSH). The signal that tells melanocytes to upregulate tyrosinase expression is intercepted before it reaches the tyrosinase level.
- ✓Upstream intervention — This makes TXA uniquely valuable in PIH formulas: it works at Stage 1 of the melanin cascade, before tyrosinase inhibitors (Alpha-Arbutin, Kojic Acid) even become relevant. No single tyrosinase inhibitor can replicate this upstream effect.
TXA's efficacy comes from its molecular identity — it is a lysine analogue that fits specific binding sites. The purity and identity verification on the COA directly determine whether you have the compound capable of this mechanism. This is why COA quality matters, not marketing language about "clinical-grade" or "premium quality."
Use concentration — what the data supports
- ✓2–3% — Primary evidence-supported concentration range for topical TXA in PIH treatment. Multiple published clinical studies on topical TXA use 2–3% and demonstrate significant reduction in melanin index versus control. This is the recommended concentration range for formulas making evidence-based brightening claims.
- ✓3–5% — Upper cosmetic use range. Some formulas use up to 5% for intensive PIH treatment serums. Efficacy data above 3% is less differentiated — the dose-response relationship for topical TXA appears to plateau in published studies. Use above 3% is typically a marketing decision rather than an efficacy one.
- ⚠Below 1% — Limited topical efficacy data at this range. TXA at below 1% may contribute to a formula as a supporting ingredient but should not carry primary brightening claims. If cost pressure pushes toward sub-1% inclusion, consider whether a different mechanism active (Alpha-Arbutin, Niacinamide) might better serve the formula goal at that concentration.
- ⚠Above 5% — Approaching the practical solubility limit in water (approximately 8–10%). No significant additional efficacy data supports concentrations above 5% for topical use. Not recommended.
Formulation notes — TXA is one of the easiest actives to work with
One of Tranexamic Acid's most commercially valuable attributes is its formulation friendliness. Unlike Glutathione (oxygen-sensitive), Kojic Acid (strict pH requirement), or Glabridin (oil-soluble only), TXA imposes almost no special formulation constraints.
- ✓Water phase addition, no heating required — TXA dissolves readily in water at ambient temperature at all cosmetic use concentrations (2–5%). Simply add to the water phase at room temperature. No pre-dissolution solvent, no heating, no special processing.
- ✓Stable across pH 4.0–7.5 — TXA is chemically stable across the full cosmetic pH range. No acidic pH requirement (unlike L-Ascorbic Acid), no alkaline instability (unlike some peptides). Formula pH can be optimised for other actives without compromising TXA stability.
- ✓Heat-stable to 80°C — TXA can be added to the heated water phase if preferred for process efficiency. No cool-down addition requirement. This simplifies manufacturing protocols for complex emulsions.
- ✓No special packaging required — TXA does not require airless, opaque, or amber packaging for stability. Standard pump or airless dispensing is appropriate. This reduces packaging cost compared to oxygen-sensitive actives.
- ✓Colourless and odourless — TXA is a white crystalline powder that produces a clear, colourless solution. No colour contribution to the finished formula — the formula appearance is fully controlled by other ingredients and pigments.
Compatibility — TXA works with everything
| Co-ingredient | Compatibility | Notes |
|---|---|---|
| Niacinamide (4–5%) | EXCELLENT | Classic PIH combination. TXA inhibits signal upstream; Niacinamide inhibits melanosome transfer downstream. Complementary mechanisms, no interaction at pH 5.5–6.5. |
| Alpha-Arbutin (1–2%) | EXCELLENT | Three-node PIH coverage: TXA (signal), Alpha-Arbutin (tyrosinase), Niacinamide (transfer). Gold standard brightening combination — all water-soluble, compatible at pH 5.5–6.5. |
| 3-O-Ethyl Ascorbic Acid | COMPATIBLE | Compatible across pH 5.0–6.5. 3-O-EAA adds antioxidant + direct brightening mechanism. Verify pH compatibility at your specific concentrations. |
| Peptides (Matrixyl, AH-8) | COMPATIBLE | No known interaction with cosmetic peptides at typical use levels. TXA + peptides is a natural combination for anti-aging brightening formulas. |
| Hyaluronic Acid | COMPATIBLE | No interaction. Both water-phase ingredients. Common in brightening serum architectures. |
| Retinol / Retinoids | NOTE pH | Compatible chemically. Retinoids prefer slightly higher pH (5.5–6.5) while TXA is stable across this range. Confirm stability of the retinoid in your specific formula pH. |
| AHAs (Glycolic, Lactic) | NOTE pH | TXA stable at AHA-required low pH (3.5–4.0). Confirm AHA concentration does not drive pH below TXA's effective range for the specific claim. |
| Standard preservatives | COMPATIBLE | Compatible with phenoxyethanol, sodium benzoate, potassium sorbate, ethylhexylglycerin systems at standard concentrations. |
COA checklist for Tranexamic Acid
- ✓CAS number: 1197-18-8 — Verify. Tranexamic Acid's CAS is unambiguous — no stereoisomer confusion risk like Alpha-Arbutin, no reduced/oxidised form distinction like Glutathione. The CAS confirmation is straightforward.
- ✓HPLC purity ≥98% with chromatogram — For cosmetic grade. The chromatogram should show a clean dominant peak at the expected retention time with minor impurity peaks below 2% each. Pharmaceutical grade requires ≥99.0% per the relevant pharmacopeial monograph.
- ✓Appearance: white crystalline powder — Any yellowing or off-white coloration is atypical and should be queried. TXA is a well-characterised compound with a consistent white appearance.
- ✓Heavy metals: Pb, As, Cd, Hg quantitative — Required. Not "Pass" — actual measured values. TXA is a synthetic compound and heavy metal contamination risk is lower than for botanical extracts, but verification is still required for regulatory documentation.
- ✓Residual solvents — TXA synthesis involves organic solvents. Request residual solvent testing confirming levels below applicable limits. For EU market, compliance with ICH Q3C or equivalent.
- ✓pH of 1% solution — Typically pH 6.5–7.5 for TXA. A result significantly outside this range may indicate the wrong compound or contamination.
- ✓Lot number and test date matching batch — Standard batch-specific COA requirements. See the COA Reading Guide for full checklist.
- ⚠MSDS and TDS for EU PIF — Confirm your supplier can provide MSDS in GHS format and a Technical Data Sheet with cosmetic use guidance suitable for EU Product Information File compilation. This is required documentation for EU market launch and should be requested before ordering.
Regulatory status — cosmetic vs pharmaceutical claims
Tranexamic Acid's pharmaceutical history creates one specific regulatory caution for cosmetic use: claim positioning.
Safe positioning: "brightening," "helps reduce the appearance of dark spots," "supports an even skin tone," "PIH-targeting formula."
Avoid: Any language referencing bleeding, coagulation, fibrinolysis, or therapeutic treatment of skin conditions. These cross into drug claim territory in most jurisdictions and will trigger regulatory review.
On the ingredient approval side, TXA is in a straightforward position for cosmetic use across all major markets: permitted in the EU (CosIng listed, no concentration restriction), China (IECIC), Japan, and the US. No pre-market approval is required in any of these markets for the cosmetic application. Supplier documentation should confirm CosIng compliance for EU market use.